- Home
- MCN vs ATRA Comparison
MCN vs ATRA Comparison
Compare MCN & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCN | ATRA |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.5M | 94.2M |
| IPO Year | 2004 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MCN | ATRA |
|---|---|---|
| Price | $5.34 | $9.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $13.67 |
| AVG Volume (30 Days) | ★ 64.4K | 35.8K |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | ★ 9.96% | N/A |
| EPS Growth | N/A | ★ 122.52 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $120,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,334.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.18 | $3.92 |
| 52 Week High | $6.20 | $19.15 |
Technical Indicators
Market Signals| Indicator | MCN | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 43.90 | 54.95 |
| Support Level | $5.18 | $8.96 |
| Resistance Level | $5.69 | $9.64 |
| Average True Range (ATR) | 0.06 | 0.70 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 78.20 | 80.10 |
Price Performance
Historical ComparisonAbout MCN Madison Covered Call & Equity Strategy Fund
XAI Madison Equity Premium Income Fund is an investment management company. The Fund invests in an actively managed equity portfolio comprised of individual stocks and covered call options. The Fund's primary investment objective is to provide high level of current income and gains, with a secondary objective of capital appreciation.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.